Literature DB >> 15645660

Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.

Yasuyuki Kamata1, Hiroyuki Nara, Takeshi Kamimura, Kengo Haneda, Masahiro Iwamoto, Junichi Masuyama, Hitoaki Okazaki, Seiji Minota.   

Abstract

A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide. Because all bacteriology findings were negative, steroid pulse-therapy was initiated promptly due to the rapidity of chest X-ray progression and the deterioration of arterial blood oxygen pressure. Although cough was induced by methotrexate, interstitial pneumonia was not detected clinically before leflunomide administration. He finally died of respiratory failure 128 days after the onset of acute interstitial pneumonia. According to the post-market surveillance, as high as approximately 1.1% of the patients on,leflunomide have developed interstitial pneumonia in Japan. It is important to emphasize that acute interstitial pneumonia due to leflunomide is a very severe and potentially fatal side effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15645660     DOI: 10.2169/internalmedicine.43.1201

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  15 in total

1.  Leflunomide in combination therapy for rheumatoid arthritis.

Authors:  Ruth L Savage
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

2.  [Acute on chronic respiratory failure in interstitial pneumonias].

Authors:  M Westhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-16       Impact factor: 0.840

Review 3.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

4.  Cu,Zn-Superoxide Dismutase-Mediated Redox Regulation of Jumonji Domain Containing 3 Modulates Macrophage Polarization and Pulmonary Fibrosis.

Authors:  Chao He; Jennifer L Larson-Casey; Linlin Gu; Alan J Ryan; Shubha Murthy; A Brent Carter
Journal:  Am J Respir Cell Mol Biol       Date:  2016-07       Impact factor: 6.914

5.  Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.

Authors:  Akihiko Gotoh; Kazuma Ohyashiki; Kazuo Oshimi; Noriko Usui; Tomomitsu Hotta; Kazuo Dan; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

6.  The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China.

Authors:  Yu-Qiong Zou; Ya-Song Li; Xiao-Nan Ding; Zhen-Hua Ying
Journal:  Rheumatol Int       Date:  2010-12-05       Impact factor: 2.631

Review 7.  Leflunomide: friend or foe for systemic lupus erythematosus?

Authors:  Guo-Cui Wu; Xiao-Di Xu; Qiong Huang; Hua Wu
Journal:  Rheumatol Int       Date:  2012-09-08       Impact factor: 2.631

Review 8.  Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.

Authors:  Nicola Alcorn; Sarah Saunders; Rajan Madhok
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide.

Authors:  Ildiko Fanny Horvath; Antonia Szanto; Zoltan Csiki; Peter Szodoray; Margit Zeher
Journal:  Pathol Oncol Res       Date:  2008-04-08       Impact factor: 3.201

10.  Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma.

Authors:  Mark J Hamblin; Maureen R Horton
Journal:  Pulm Med       Date:  2011-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.